At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AAPG ASCENTAGE PHARMA GROUP
Post-Mkt 11-13 18:03:47 EST
14.62
-0.40
-2.66%
盘后14.88
+0.26+1.79%
16:10 EST
High14.89Low14.62Vol8.74K
Open14.69D1 Closing15.02Amplitude1.80%
Mkt Cap1.36BTradable Cap1.05BTotal Shares93.33M
T/O129.11KT/O Rate0.01%Tradable Shares71.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ascentage Pharma (06855) Shares Rise Over 5% on Multiple Clinical Advancements to Be Presented at ASH Annual Meeting, APG-5918 Receives Oral Presentation Upon First Disclosure
Stock News  ·  11-05
Ascentage Pharma (06855) Shares Rise Over 5% on Multiple Clinical Advancements to Be Presented at ASH Annual Meeting, APG-5918 Receives Oral Presentation Upon First Disclosure
Ascentage Pharma Trustee Buys 200,000 Shares for 2022 Restricted Share Unit Plan
Stock News  ·  10-27
Ascentage Pharma Trustee Buys 200,000 Shares for 2022 Restricted Share Unit Plan
Ascentage Pharma Trustee Acquires 200,000 Shares for 2022 Restricted Share Unit Plan
Stock News  ·  10-22
Ascentage Pharma Trustee Acquires 200,000 Shares for 2022 Restricted Share Unit Plan
Ascentage Pharma's Lisaftoclax Granted China Breakthrough Designation
MT Newswires Live  ·  10-21
Ascentage Pharma's Lisaftoclax Granted China Breakthrough Designation
Ascentage Pharma Shares Rise Over 4% in Early Trading as Lisaftoclax Receives Breakthrough Therapy Designation from Drug Review Center
Stock News  ·  10-21
Ascentage Pharma Shares Rise Over 4% in Early Trading as Lisaftoclax Receives Breakthrough Therapy Designation from Drug Review Center
Ascentage Pharma initiated with an Outperform at William Blair
TIPRANKS  ·  10-16
Ascentage Pharma initiated with an Outperform at William Blair
Ascentage Pharma Group International : Citigroup Initiates Coverage with Buy Rating; Target Price $46
THOMSON REUTERS  ·  10-14
Ascentage Pharma Group International : Citigroup Initiates Coverage with Buy Rating; Target Price $46
Ascentage Pharma: A Dancer on the High Wire
Deep News  ·  10-09
Ascentage Pharma: A Dancer on the High Wire
Ascentage Pharma Group International : JP Morgan Cuts Target Price to $33 from $46
THOMSON REUTERS  ·  10-08
Ascentage Pharma Group International : JP Morgan Cuts Target Price to $33 from $46
Ascentage Pharma Trustee Acquires 50,000 Shares for 2022 Restricted Share Unit Scheme
Stock News  ·  09-17
Ascentage Pharma Trustee Acquires 50,000 Shares for 2022 Restricted Share Unit Scheme
Analysts Offer Insights on NA Companies: PACS Group Inc (PACS) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
TIPRANKS  ·  09-02
Analysts Offer Insights on NA Companies: PACS Group Inc (PACS) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
GlobeNewswire  ·  09-02
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Oppenheimer Keeps Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)
TIPRANKS  ·  08-21
Oppenheimer Keeps Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)
Ascentage Pharma H1 Loss Widens, Revenue Rises
MT Newswires Live  ·  08-20
Ascentage Pharma H1 Loss Widens, Revenue Rises
Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
Benzinga Earnings  ·  08-20
Reported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion
Stock News  ·  08-20
Ascentage Pharma Reports 2026 Interim Results: Strengthening Commercial Engine and Accelerating Global Expansion
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
GlobeNewswire  ·  08-20
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
GlobeNewswire  ·  08-13
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Earning Preview: ASCENTAGE PHARMA GROUP this quarter’s revenue is expected to increase by 58.18%, and institutional views are bullish
Earnings Agent  ·  08-12
Earning Preview: ASCENTAGE PHARMA GROUP this quarter’s revenue is expected to increase by 58.18%, and institutional views are bullish
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
GlobeNewswire  ·  08-05
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Introduction

Company Name.
ASCENTAGE PHARMA GROUP
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascentage Pharma Group is a holding company primarily engaged in the discovery, development, and commercialization of therapeutics for hematologic malignancies. Its core business focuses on developing and selling novel small-molecule therapies targeting cancer, hepatitis B, and age-related diseases. Key products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), and APG-5918, which are mainly used to treat hematologic malignancies such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and multiple myeloma. The company primarily operates in the domestic Chinese market.
Issue price:
--